{"url_path":"/sec/qubt/8-k/2026-07-22/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1758009/0001213900-26-080443-index.html","accession_number":"0001213900-26-080443","cik":"0001758009","ticker":"QUBT","issuer_name":"Quantum Computing Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1758009/0001213900-26-080443-index.html","primary_entity_key":"0001758009","primary_entity_name":"Quantum Computing Inc."},"word_count":77,"has_tables":true,"body_markdown":"**Item 5.02 Departure of Directors or Certain\nOfficers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nOn July 17, 2026, Dr. Pouya Dianat ceased serving\nas the Company’s Chief Revenue Officer and transitioned to the newly created role of Chief Product Officer, effective immediately,\nfocusing on product development. This transition was mutually agreed between Dr. Dianat and the Company, and Dr. Dianat’s compensation\narrangement was not materially changed in connection with the transition."}